Stocks With Rising Relative Price Strength: Achaogen – Investor's Business Daily

This post was originally published on this site

The Relative Strength (RS) Rating for Achaogen (AKAO) jumped into a new percentile Thursday, with a rise from 80 to 83.

XAutoplay: On | Off IBD’s unique RS Rating identifies market leadership by showing how a stock’s price movement over the last 52 weeks compares to that of other stocks on the major indexes.

History shows that the best stocks tend to have an RS Rating of above 80 as they begin their biggest runs.


Looking For Winning Stocks? Try This Simple Routine


Achaogen is now considered extended and out of buy range after clearing a 6.18 buy point in a first-stage cup without handle. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line.

The company reported negative growth for both the top and bottom lines last quarter.

Achaogen holds the No. 211 rank among its peers in the Medical-Biomed/Biotech industry group. Corcept Therapeutics (CORT), Ligand Pharmaceuticals (LGND) and Xoma (XOMA) are among the top 5 highly rated stocks within the group.

RELATED:

Biotech And Pharmaceutical Industry And Stock News

Stocks With Rising Relative Strength Ratings

Why Should You Use IBD’s Relative Strength Rating?

How Relative Strength Line Can Help You Judge A Stock

This post was originally published on *this site*